Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyHead and Neck OncologyNeuro-OncologyThoracic TumorsTumor, regardless of entityDiseaseBile Duct CarcinomaColon CancerOvarian TumorPancreatic CancerTumor Biomarker DefinedSubgroupBRAF V600-MutationHER2+ICD10C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C24.-C24.0C24.1C24.8C24.9C25.-C56MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsColonic NeoplasmsColorectal NeoplasmsCommon Bile Duct NeoplasmsNeoplasmsPancreatic NeoplasmsSequencePERT840/TRAS8, colorect. Ca, C1 (PID1533) -|- PERT420/TRAS6, C2+ (PID1534)ChemotherapyChemo-substanceDabrafenibPembrolizumabPertuzumabTrametinibTrastuzumabTrastuzumab emtansineChemo-substanceDabrafenibPembrolizumabPertuzumabTrametinibTrastuzumabTrastuzumab emtansineChemo-substanceDabrafenibPembrolizumabPertuzumabTrametinibTrastuzumabTrastuzumab emtansineChemo-substanceDabrafenibPembrolizumabPertuzumabTrametinibTrastuzumabTrastuzumab emtansineNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances12Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseneoadjuvantTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlAstheniaCardiotoxicityDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHepatotoxicityHyperbilirubinemiaHyperglycemiaHyperthyroidismHypokalemiaHyponatremiaHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesNeuropathyNeutropeniaPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorJhaveri KLLudford KMeric-Bernstam FSalama AKSDiseaseLokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2Lokal fortgeschrittener, nicht metastasierter solider Tumor, dMMR/MSI-HMetastasiertes therapieresistentes Kolonkarzinom, Her2 amplifiziert, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1OriginDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)The University of Texas MD Anderson Cancer Center, Houston, TX, USAUniversity of Texas MD Anderson Cancer Center, Houston, USA, MyPathway trialProtocols in Revision 5 protocols foundDabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)Pembrolizumab 200, Tumor Biomarker Defined, neoadjuvant (PID2956 V1.0)Pertuzumab 420 / Trastuzumab 6, Tumor Biomarker Defined, Cycle 2+ (PID1534 V1.1)Pertuzumab 840 / Trastuzumab 8, Tumor Biomarker Defined, Cycle 1 (PID1533 V1.1)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)
